Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Fidia Spa ( (IT:FDA) ) has provided an announcement.
Fidia S.p.A. has issued the fourth tranche of its 2026 reserved convertible bond with warrants to Global Growth Holding Limited, placing 25 bonds for a nominal €250,000 and granting 3,125,000 new warrants exercisable into shares at €0.08 each. The warrants are not listed, have a five‑year term, and bring the total outstanding POC‑related warrants to 10,625,000, reinforcing GGHL’s option‑based exposure to Fidia’s equity.
In parallel, GGHL converted three of the newly issued bonds into one million Fidia shares at €0.03 per share, increasing subscribed capital under the POC to €780,000 and the company’s share capital to €10,627,761.90. Following this conversion, Fidia now has 42,542,927 shares in issue and 22 POC bonds still outstanding, signalling continued dilution but also ongoing investor support to finance the group’s activities in high‑tech milling and numerical control systems.
The most recent analyst rating on (IT:FDA) stock is a Sell with a EUR0.11 price target. To see the full list of analyst forecasts on Fidia Spa stock, see the IT:FDA Stock Forecast page.
More about Fidia Spa
Fidia S.p.A., based in Turin and listed on Euronext Milan, is a global player in numerical control technology and high‑performance integrated milling systems. With over 50 years of experience and around 135 employees, it serves mainly the automotive mould and aerospace sectors, offering numerical controls, high‑speed milling machines and CAM software that span the entire milling process from programming to finished part.
Average Trading Volume: 1,211,278
Technical Sentiment Signal: Strong Sell
Current Market Cap: €999.5K
For a thorough assessment of FDA stock, go to TipRanks’ Stock Analysis page.